Atlas Trials

Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)

Clinical trial NCT06844422 · RECRUITING

Trial details

NCT number
NCT06844422
Sponsor
Shandong Cancer Hospital and Institute
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2025-02-08
Primary completion
2028-02-18
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.